Answers are grounded in this paper and cite their sources.
Maternal obesity during the perinatal period promotes adverse metabolic programming in offspring, increasing susceptibility to metabolic disorders later in life. Myo‐inositol (MI), a bioactive compound abundant in breast milk, has shown short‐term benefits when supplemented during lactation. This study evaluated the long‐term effects of maternal MI supplementation during lactation on metabolic and cognitive health in offspring born to diet‐induced obese or standard chow diet (SD)‐fed dams, all challenged with a Western diet (WD) in adulthood. Wistar rats were fed a SD or WD from 1 month before mating and through gestation and lactation and treated with MI (200 mg/kg/day) or vehicle during lactation. Offspring were fed a SD from weaning to 4 months of age, followed by a WD until sacrifice at 6 months. In male offspring, maternal MI supplementation improved insulin sensitivity (lower insulin levels and HOMA‐IR), increased circulating BDNF (WD group), and enhanced cognitive performance. It also increased adipose GLUT4 levels and Bdnf expression and, in the liver, downregulated lipogenic genes, upregulated Bdnf , and reduced lipid content, with sex‐specific differences. These effects were accompanied by lower circulating levels of triglycerides, nonesterified fatty acids, and TNF‐α. Collectively, these findings indicate that maternal MI supplementation during lactation enhances offspring metabolic resilience and cognitive outcomes through integrated improvements in insulin signaling, lipid metabolism, and inflammatory regulation, partially mitigating the detrimental effects of maternal obesity and adult obesogenic diet in a sex‐specific manner.
No takes yet. Share an insight, caveat, or question.
Valle et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: